SequelSEC

Cryoport, Inc. CYRX

Pharmaceutical Preparations · CIK 0001124524 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$48.97M
Fiscal year ended 2026-06-30
Operating income
-$10.04M
Fiscal year ended 2026-06-30
Free cash flow
-$7.97M
Fiscal year ended 2026-06-30

Cryoport, Inc. (CYRX) reported revenue of $48.97M and net income of -$8.26M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Cryoport, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Cryoport, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$48.97M$47.80M$45.45M$44.23M$45.45M$41.04M$41.45M$38.32M$39.71M$37.29M
Cost of revenue$26.15M$25.88M$23.74M$22.91M$24.08M$22.40M$21.96M$20.88M$22.05M$22.23M
Gross profit$22.82M$21.91M$21.71M$21.32M$21.38M$18.64M$19.49M$17.44M$17.66M$15.06M
Operating income-$10.04M-$9.61M-$10.03M-$9.93M-$9.65M-$7.19M-$12.74M-$13.39M-$78.03M-$17.51M
Net income-$8.26M-$10.54M-$11.64M-$6.94M$108.87M-$11.98M-$18.68M$805.00K-$77.99M-$18.90M
Research & development$4.85M$3.91M$4.47M$4.52M$4.12M$3.93M$4.16M$4.16M$4.65M$4.75M
Weighted-average diluted sharesshares 50.44Mshares 49.90MUnavailableshares 50.13Mshares 50.26Mshares 49.95MUnavailableshares 49.42Mshares 49.35Mshares 49.02M
Pretax income-$7.75M-$9.32M-$7.40M-$6.53M-$11.74M-$6.50M-$17.31M$4.24M-$76.35M-$14.92M
Income tax expense$505.00K$108.00K$1.13M$165.00K$274.00K$234.00K-$134.00K$316.00K$66.00K$111.00K
Diluted EPS$-0.20$-0.25Unavailable$-0.18$2.13$-0.28Unavailable$-0.02$-1.62$-0.43
Selling, general & administrative$28.01M$27.62M$27.28M$26.73M$26.91M$21.90M$28.08M$26.67M$27.24M$27.82M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Cryoport, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$269.27M$272.91M$250.49M$255.81M$243.42M$36.10M$34.14M$31.37M$34.18M$39.29M
Total assets$756.20M$763.61M$764.99M$774.33M$773.93M$699.84M$703.49M$701.76M$852.34M$942.85M
Current assets$460.20M$470.54M$476.17M$484.84M$489.49M$411.28M$341.57M$350.34M$501.99M$525.70M
Total liabilities$265.50M$268.62M$262.35M$261.06M$258.54M$301.03M$301.59M$283.19M$452.25M$470.66M
Current liabilities$221.04M$224.87M$219.02M$30.75M$30.15M$74.03M$64.56M$61.44M$59.88M$48.98M
Total equity incl. NCI$490.70M$494.99M$502.64M$513.27M$519.08M$398.81M$401.90M$418.57M$400.10M$472.19M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$21.51M$21.75M$23.19M$23.33M$23.04M$23.34M$21.48M$23.55M$23.61M$25.02M
Accounts receivable$36.45M$39.00M$33.36M$34.91M$33.41M$28.37M$25.30M$43.46M$40.16M$41.25M
Goodwill$22.07M$22.14M$22.40M$22.41M$18.71M$20.96M$20.57M$54.06M$52.38M$107.59M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Cryoport, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$1.13M$3.74M$919.00K$2.19M-$7.34M-$4.34M-$5.48M$447.00K-$8.02M-$3.26M
Capital expenditures$9.10M$9.98M$5.47M$3.45M$4.35M$3.17M$5.22M$4.24M$3.79M$4.01M
Investing cash flow-$5.81M$18.72M$56.00K$14.31M$230.04M$5.92M$3.48M$153.57M$13.32M$6.44M
Financing cash flow$653.00K$85.00K-$2.15M-$2.87M-$15.86M-$189.00K$2.01M-$155.29M-$8.76M$512.00K
Net change in cash-$3.64M$22.42M-$5.32M$12.40M$196.06M$2.07M$624.00K-$1.79M-$3.20M$3.32M
Stock-based compensation$2.40M$2.40M$2.43M$2.53M$2.04M$3.06M$3.64M$4.06M$4.20M$4.67M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$2.01M$3.74MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$6.59M$6.40M$6.36M$6.42M$7.30M$7.65M$7.89M$7.84M$7.56M$7.47M

Derived

Cryoport, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$7.97M-$6.25M-$4.55M-$1.26M-$11.70M-$7.51M-$10.70M-$3.79M-$11.82M-$7.27M
Gross margin46.6%45.8%47.8%48.2%47.0%45.4%47.0%45.5%44.5%40.4%
Operating margin-20.5%-20.1%-22.1%-22.5%-21.2%-17.5%-30.7%-34.9%-196.5%-46.9%
FCF margin-16.3%-13.1%-10.0%-2.9%-25.7%-18.3%-25.8%-9.9%-29.8%-19.5%
SBC / revenue4.9%5.0%5.3%5.7%4.5%7.5%8.8%10.6%10.6%12.5%
Current ratio2.08x2.09x2.17x15.77x16.24x5.56x5.29x5.70x8.38x10.73x
Revenue YoY growth7.7%16.5%9.6%15.4%14.5%10.1%Unavailable-31.8%-30.4%-40.6%
Net margin-16.9%-22.1%-25.6%-15.7%239.5%-29.2%-45.1%2.1%-196.4%-50.7%
R&D / revenue9.9%8.2%9.8%10.2%9.1%9.6%10.0%10.8%11.7%12.7%
CapEx / revenue18.6%20.9%12.0%7.8%9.6%7.7%12.6%11.1%9.5%10.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable7.5%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CYRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-06-30

Difference 3689000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.